title: Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by beta-cyclodextrin derivatives in hydrophilic ointment.
abstract: The enhancing effects of heptakis(2,6-di-O-methyl)-beta-cyclodextrin (DM-beta-CyD) and 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CyD) on the percutaneous absorption of 4-biphenylylacetic acid (BPAA), a nonsteroidal anti-inflammatory drug, in hydrophilic ointment were studied and compared with the parent beta-cyclodextrin (beta-CyD). 13C-NMR measurements suggested that the biphenyl group of BPAA is preferably included within the cavity of three beta-CyDs. The three beta-CyDs remarkably enhanced the release of BPAA from the hydrophilic ointment base and the in vitro cutaneous permeation, depending on the increase in solubility of BPAA in the ointment base. Pretreatment of the ointment containing DM-beta-CyD or HP-beta-CyD onto the isolated skin of hairless mice, however, provided no effects on the skin permeation of BPAA. When propylene glycol was used as a vehicle, both the release rate and cutaneous permeation parameters showed no appreciable difference between BPAA alone and its HP-beta-CyD complex, because the solubilities of BPAA and its HP-beta-CyD complex were almost comparable in the vehicle. The present results suggested that the enhancing effect of beta-CyDs on the percutaneous absorption of BPAA can be mainly ascribed to an increase in the solubility of BPAA in the hydrophilic ointment.
authors.affiliation: Faculty of Pharmaceutical Sciences, Kumamoto University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Arima
authors.forename: T
authors.initials: T
authors.lastname: Miyaji
authors.forename: T
authors.initials: T
authors.lastname: Irie
authors.forename: F
authors.initials: F
authors.lastname: Hirayama
authors.forename: K
authors.initials: K
authors.lastname: Uekama
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003505:Cyclodextrins / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008819:Mice, Nude; D009824:Ointments; D010648:Phenylacetates / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011409:Propylene Glycols; D051381:Rats; D012869:Skin Absorption / Q000187:drug effects*; D012995:Solubility; D013268:Stimulation, Chemical; D047392:beta-Cyclodextrins
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003505:Cyclodextrins; D009824:Ointments; D010648:Phenylacetates; D011409:Propylene Glycols; D047392:beta-Cyclodextrins; C012776:biphenylylacetic acid; C031215:betadex